Substrate

Bibliography

Biblio print

Tree Display

AceDB Schema

XML Display

Feedback

Substrate Report for: Idalopirdine-rivastigmine

butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist. BuChE (IC50 = 0.97 microM). After hydrolysis a potent 5-HT6 receptors antagonist (Ki = 11.4 nM) related to idalopirdine is released


General
Type Drug, Pro-Drug, Carbamate, Derivative of Rivastigmine, Multitarget, 5-HT-receptor-ligand
Chemical_Nomenclature
Canonical SMILES C1(=C[N]C2=CC(=CC=C12)F)CCNCC3=CC(=CC=C3)OC(=O)N(C)CC
InChI InChI=1S/C21H24FN3O2/c1-3-25(2)21(26)27-18-6-4-5-15(11-18)13-23-10-9-16-14-24-20-12-17(22)7-8-19(16)20/h4-8,11-12,14,23-24H,3,9-10,13H2,1-2H3
InChIKey QZGAFMLTVWNDEJ-UHFFFAOYSA-N
Other name(s)
________________________________________________________________________________________________
MW|369.43
Formula|C21H24FN3O2
CAS_number|
PubChem|
UniChem|QZGAFMLTVWNDEJ-UHFFFAOYSA-N
IUPHAR|
Wikipedia|

Target
Families | Idalopirdine-rivastigmine ligand of proteins in family: BCHE
Protein | human-BCHE

References:
Search PubMed for references concerning: Idalopirdine-rivastigmine
    Title: Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT(6) receptor antagonist with therapeutic interest in Alzheimer's disease
    Toublet FX, Lalut J, Hatat B, Lecoutey C, Davis A, Since M, Corvaisier S, Freret T, Sopkova-de Oliveira Santos J and Rochais C <3 more author(s)>
    Ref: Eur Journal of Medicinal Chemistry, 210:113059, 2020 : PubMed